Medtronic (MDT) Gets FDA Approval for Resolute Integrity DES
Tweet Send to a FriendGet Alerts MDT Hot Sheet
Price: $51.46 -0.14%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 2.7%
EPS Growth %: +11.1%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 2.7%
EPS Growth %: +11.1%
Trade MDT Now!
Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD).
The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently powerful clinical performance across a broad spectrum of patients –– including those with diabetes, a common contributor to coronary artery disease that complicates treatment. The Resolute DES uses the same drug-and-polymer combination as the Resolute Integrity DES.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently powerful clinical performance across a broad spectrum of patients –– including those with diabetes, a common contributor to coronary artery disease that complicates treatment. The Resolute DES uses the same drug-and-polymer combination as the Resolute Integrity DES.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Medtronic (MDT) Receives CE Mark for Export Advance Catheter
- Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
- Tempur-Pedic (TPX) is Now 'Tempur Sealy International'
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
